Amifostine
Back to searchMolecule Structure
Scientific Name
Amifostine
Description of the Drug
Amifostine is a cytoprotective adjuvant used for reduction in the cumulative renal toxicity in patients with ovarian cancer and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01143
http://www.drugbank.ca/drugs/DB01143
Brand Name(s)
Amifostine, Ethyol
Company Owner(s)
Eugia Pharma Specialities Ltd, Sun Pharmaceutical Industries Ltd, Clinigen Inc
Mechanism(s) Of Action
Not Available
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL18464 | ||
| PharmGKB | PA448365 | ||
| Human Metabolome Database | HMDB0015274 | ||
| DrugBank | DB01143 | ||
| PubChem: Thomson Pharma | 14797785 | ||
| PubChem | 29927142 | 2141 | |
| LINCS | LSM-4721 | ||
| Nikkaji | J23.675F | ||
| EPA CompTox Dashboard | DTXSID8022585 | ||
| DrugCentral | 156 | ||
| ChemicalBook | CB1316377 | CB4316378 | |
| rxnorm | AMIFOSTINE | ETHYOL | AMIFOSTINE ANHYDROUS |
| KEGG Ligand | C06819 | ||
| ChEBI | 2636 | ||
| ZINC | ZINC000021992285 |
